GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » Construction In Progress

NGENF (NervGen Pharma) Construction In Progress : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Construction In Progress?


NervGen Pharma Construction In Progress Historical Data

The historical data trend for NervGen Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Construction In Progress Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NervGen Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


NervGen Pharma Business Description

Traded in Other Exchanges
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

NervGen Pharma Headlines

From GuruFocus